Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES PHENYTOIN ORAL SUSPENSION, USP Generic of DILANTIN-125®

PEAPACK, N.J., October 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Phenytoin Oral Suspension, USP to its ever-expanding generic pharmaceutical product line.

Greenstone’s Phenytoin Oral Suspension, USP product is the authorized generic of, and equivalent to the innovator’s product, DILANTIN-125® (phenytoin oral suspension). Their new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the power and scale of Pfizer’s 163-year worldwide reputation for a commitment to integrity, quality, and supply reliability. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients they serve.

See the Full Prescribing Information, for Greenstone’s Trifluridine Ophthalmic Solution at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.